4//SEC Filing
Mylet Johanna 4
Accession 0001209191-21-070938
CIK 0001661460other
Filed
Dec 21, 7:00 PM ET
Accepted
Dec 22, 4:53 PM ET
Size
10.8 KB
Accession
0001209191-21-070938
Insider Transaction Report
Form 4
Mylet Johanna
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
2021-12-21$1.17/sh+2,616$3,069→ 31,131 total - Exercise/Conversion
Common Stock
2021-12-21$1.93/sh+3,100$5,992→ 34,231 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-12-21−3,100→ 3,816 totalExercise: $1.93Exp: 2028-02-05→ Common Stock (3,100 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2021-12-21−2,616→ 0 totalExercise: $1.17Exp: 2026-02-28→ Common Stock (2,616 underlying)
Footnotes (2)
- [F1]The stock option is fully vested and exercisable.
- [F2]12.5% of the shares shares subject to the stock option vested and became exercisable on August 6, 2018, and the remaining shares vest in 42 equal monthly installments thereafter.
Documents
Issuer
Poseida Therapeutics, Inc.
CIK 0001661460
Entity typeother
Related Parties
1- filerCIK 0001765988
Filing Metadata
- Form type
- 4
- Filed
- Dec 21, 7:00 PM ET
- Accepted
- Dec 22, 4:53 PM ET
- Size
- 10.8 KB